Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium longum BL21 for Prevention of Radiation Intestinal Injury in Cervical Cancer
ChiCTR2300069881Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Mar 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bifidobacterium longum BL21 in radiation enteritis, sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: CT evaluation of gastrointestinal (acute) toxicity, Fecal microbial composition and 1 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
bifidobacterium longum BL21
03
Conditions
radiation enteritis
Beyond the preview
Go deeper on ChiCTR2300069881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069881.